In this podcast, we feature an article that examines the effect of COVID-19 on drug development, clinical trials, regulatory review, and new drug approvals. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Drug development and regulatory review
- FDA’s perspective
- New drug approvals thus far in 2020
- Clinical trials and COVID-19: where the impact resides
- Companies adjust clinical-trial research strategies